Heart failure and sleep apnea: can a drug and breathing machine improve both?

NCT ID NCT07556094

Completed Disease control Sponsor: Medical University of Bialystok Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a diabetes drug called empagliflozin, combined with a breathing machine (CPAP), can improve sleep and heart function in 70 adults with both heart failure and obstructive sleep apnea. Participants were randomly assigned to take empagliflozin or not, and all started CPAP after 3 months. The goal was to see if the drug reduces sleep apnea severity and helps the heart, while also checking how well CPAP works after the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Apnea heart failure obstructive sleep apnea syndrome sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE OBSTRUCTIVE SLEEP APNEA (OSA) SLEEP APNEA SYNDROME, OBSTRUCTIVE

Contacts and locations

Locations

University Clinical Hospital in Białystok

Bialystok, Podlaskie Voivodeship, 15-276, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.